| Nabeel K Ahmed, MD | |
|
1133 Medical Dr, Tyler, TX 75701-2130 | |
| (903) 595-5486 | |
| (903) 595-5128 |
| Full Name | Nabeel K Ahmed |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 33 Years |
| Location | 1133 Medical Dr, Tyler, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003965906 | NPI | - | NPPES |
| 047138501 | Medicaid | TX | |
| 2002214870 A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | K7963 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Palestine Diaysis Center | Palestine, TX | Dialysis facility |
| Ut Health East Texas Tyler Regional Hospital | Tyler, TX | Hospital |
| Christus Mother Frances Hospital | Tyler, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tyler Nephrology Associates Pa | 6901862242 | 24 |
News Archive
Medication non-adherence is as dangerous and costly as many diseases, causing up to 125,000 deaths annually in the U.S. Non-adherence, the failure to take drugs on time in the dosages prescribed, has been described as the world's "other drug problem."
Hyperfine Research Inc. announced today its collaboration with the Yale School of Medicine to pioneer the use of the world's first portable, low-cost magnetic resonance imaging system at the bedside of patients in the neuro intensive care unit of Yale New Haven Hospital. Hyperfine's system can move directly to the bedside, plug into a wall outlet, and operate in any healthcare setting.
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Four out of five people with a hidden brain condition that causes limb weakness or paralysis experience lasting physical difficulties.
› Verified 3 days ago
| Entity Name | Tyler Nephrology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942360326 PECOS PAC ID: 6901862242 Enrollment ID: O20041208000236 |
News Archive
Medication non-adherence is as dangerous and costly as many diseases, causing up to 125,000 deaths annually in the U.S. Non-adherence, the failure to take drugs on time in the dosages prescribed, has been described as the world's "other drug problem."
Hyperfine Research Inc. announced today its collaboration with the Yale School of Medicine to pioneer the use of the world's first portable, low-cost magnetic resonance imaging system at the bedside of patients in the neuro intensive care unit of Yale New Haven Hospital. Hyperfine's system can move directly to the bedside, plug into a wall outlet, and operate in any healthcare setting.
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Four out of five people with a hidden brain condition that causes limb weakness or paralysis experience lasting physical difficulties.
› Verified 3 days ago
| Entity Name | Etmc Physician Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609382662 PECOS PAC ID: 4486915600 Enrollment ID: O20180305002106 |
News Archive
Medication non-adherence is as dangerous and costly as many diseases, causing up to 125,000 deaths annually in the U.S. Non-adherence, the failure to take drugs on time in the dosages prescribed, has been described as the world's "other drug problem."
Hyperfine Research Inc. announced today its collaboration with the Yale School of Medicine to pioneer the use of the world's first portable, low-cost magnetic resonance imaging system at the bedside of patients in the neuro intensive care unit of Yale New Haven Hospital. Hyperfine's system can move directly to the bedside, plug into a wall outlet, and operate in any healthcare setting.
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Four out of five people with a hidden brain condition that causes limb weakness or paralysis experience lasting physical difficulties.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nabeel K Ahmed, MD 1133 Medical Dr, Tyler, TX 75701-2130 Ph: (903) 595-5486 | Nabeel K Ahmed, MD 1133 Medical Dr, Tyler, TX 75701-2130 Ph: (903) 595-5486 |
News Archive
Medication non-adherence is as dangerous and costly as many diseases, causing up to 125,000 deaths annually in the U.S. Non-adherence, the failure to take drugs on time in the dosages prescribed, has been described as the world's "other drug problem."
Hyperfine Research Inc. announced today its collaboration with the Yale School of Medicine to pioneer the use of the world's first portable, low-cost magnetic resonance imaging system at the bedside of patients in the neuro intensive care unit of Yale New Haven Hospital. Hyperfine's system can move directly to the bedside, plug into a wall outlet, and operate in any healthcare setting.
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Four out of five people with a hidden brain condition that causes limb weakness or paralysis experience lasting physical difficulties.
› Verified 3 days ago
Ifeatu Uchenna Oti, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1133 Medical Dr, Tyler, TX 75701 Phone: 903-595-5486 Fax: 903-595-5128 | |
Preetham Reddy Muskula, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2608 Mcdonald Rd, Tyler, TX 75701 Phone: 903-595-5514 Fax: 903-262-3715 | |
Dr. Varalaxmi Bhavani Nannaka, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 912 S Fleishel Ave, Tyler, TX 75701 Phone: 903-592-6901 | |
David A Brickey, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 800 E Dawson St, Tyler, TX 75701 Phone: 903-525-1914 | |
Randy Craig Randall, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1783 Troup Highway, Tyler, TX 75701 Phone: 903-595-2283 Fax: 903-595-1063 | |
Dr. Amanda Nicole Long, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 619 S Fleishel Ave, Ste 327, Tyler, TX 75701 Phone: 903-510-1173 |